(Reuters) - NEW YORK, June 14 - A U.S. health panel's resounding rejection of Sanofi-Aventis' obesity drug Zimulti casts a pall over other experimental products in the same class while offering a stark reminder of challenges facing the development of weight-loss medications.
The Food and Drug Administration advisory panel on Wednesday unanimously recommended Zimulti not be approved because of concerns it may increase suicidal thinking and depression. The FDA is expected to make a final decision by July 26.
Read more at Reuters.com Bonds News
The Food and Drug Administration advisory panel on Wednesday unanimously recommended Zimulti not be approved because of concerns it may increase suicidal thinking and depression. The FDA is expected to make a final decision by July 26.
Read more at Reuters.com Bonds News
No comments:
Post a Comment